Skip to main content
. Author manuscript; available in PMC: 2014 Mar 15.
Published in final edited form as: Sci Transl Med. 2013 Jun 19;5(190):190ra79. doi: 10.1126/scitranslmed.3005471

Fig. 7. Evaluation of clomiphene and toremifene on Ebola virus VLP-GP1,2 internalization and cathepsin processing.

Fig. 7

(A) Clomiphene and toremifene were evaluated at 5 and 0.8 μM, respectively. EIPA is a known inhibitor of EBOV internalization. Results indicate that neither clomiphene nor toremifene inhibits EBOV internalization. (B) Clomiphene (5 μM) and toremifene (0.8 μM) were evaluated, as described in Materials and Methods, for their effects on cathepsin B (CatB) and cathepsin L (CatL) activity (singly and combined) in SNB19 cells. EST is a cysteine protease inhibitor that was included as a positive control for the assay. Data in the main plot are from the 1.5-hour time point. Data for CatL at 18 hours are shown in fig. S8.